查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830982

攝護腺癌治療市場

Prostate Cancer Therapeutics Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

攝護腺癌治療市場預計將從 2024 年的 173.7 億美元增加到 2031 年的 308.3 億美元，2025 年至 2031 年的複合年成長率預計為 8.5%。

市場洞察與分析師觀點：前列腺癌治療市場正在蓬勃發展，這得益於旨在開發新藥化合物的研發力度加大、前列腺癌發病率上升以及政府對前列腺癌診斷的支持力度加大。此外，市場參與者提供的先進產品也推動了市場擴張。 2023年1月，BDR Pharmaceuticals在印度推出了阿帕魯胺的學名藥，商品名為APATIDE，用於治療非轉移性去勢抵抗性前列腺癌和轉移性去勢敏感性前列腺癌。

成長動力與挑戰：攝護腺癌是男性最常見的健康問題之一，尤其針對50歲以上男性。肥胖或有家族病史的男性更易罹患攝護腺癌。攝護腺癌通常發展緩慢，沒有明顯症狀，因此早期發現頗具挑戰性。大多數前列腺癌起源於前列腺外周區域，通常只有當癌細胞生長到足以壓迫尿道，或出現轉移性骨痛時才會出現症狀。 50歲以上男性若有下泌尿道症狀、勃起功能障礙或血尿，應考慮攝護腺癌的可能性。在全球範圍內，攝護腺癌是男性癌症相關死亡的第五大原因，也是第二常見癌症。儘管自2000年以來前列腺癌發生率有所下降，但自2010年以來，晚期前列腺癌病例一直在上升。發病率和死亡率差異很大，已開發國家普遍報告發病率較高，但死亡率較低。在美國，攝護腺癌的風險幾乎是全球平均的四倍。根據諾華公司統計，2020年全球報告約有140萬例前列腺癌新病例，約37.5萬例死亡病例。全球前列腺癌發生率的上升和較低的檢出率是推動前列腺癌治療市場成長的關鍵因素。

策略洞察報告細分和範圍：前列腺癌治療市場按治療類型、最終用戶和地理分類。依治療類型，包括荷爾蒙療法、化療、免疫療法、標靶療法等。按最終用戶，分為醫院、專科診所和其他。依地域分類，市場細分為北美（美國、加拿大和墨西哥）、歐洲（英國、德國、法國、義大利、西班牙和歐洲其他地區）、亞太地區（中國、日本、印度、韓國、澳洲和亞太其他地區）、中東和非洲（阿拉伯聯合大公國、沙烏地阿拉伯、南非和中東和非洲其他地區）以及其他中美洲（巴西、阿根廷和南美洲和其他地區）。

分段分析：前列腺癌治療市場依治療類型細分為荷爾蒙治療、化療、免疫治療、標靶治療等。 2022 年，荷爾蒙治療領域佔據了化療之後最大的市場佔有率，預計在 2022 年至 2030 年期間實現最高複合年成長率。化療仍然是前列腺癌的重要治療方法，因為它涉及靶向和摧毀新舊癌細胞的藥物。化療可以緩解轉移性攝護腺癌的症狀，縮小腫瘤，提高生活品質。多西他賽（Taxotere）是荷爾蒙治療抗藥性患者的標準化療方案，而卡巴他賽（Jevtana）也已被 FDA 批准用於治療去勢抵抗性前列腺癌，特別是對於在多西他賽治療期間癌症進展的患者。

區域分析：前列腺癌治療市場按地區進行分析，包括北美、歐洲、亞太地區、中東和非洲以及南美和中美。北美是全球前列腺癌治療市場成長的主要貢獻者，而亞太地區預計在 2022 年至 2030 年期間的複合年成長率最高。美國前列腺癌治療市場的成長主要受前列腺癌發病率上升、新產品推出和政府措施的推動。例如，2023 年 6 月，阿斯特捷利康和默沙東的 Lynparza (olaparib) 在美國獲準用於治療疑似有害 BRCA 突變 (BRCAm) 轉移性去勢抵抗性攝護腺癌 (mCRPC) 成年患者。此外，2023 年 11 月，FDA 批准了由安斯泰來製藥美國公司生產的恩雜魯胺，用於治療具有高轉移風險的非轉移性去勢敏感性前列腺癌 (nmCSPC)。

前列腺癌治療市場報告範圍行業發展和未來機會：前列腺癌治療市場主要參與者的關鍵舉措包括：

2022年3月，美國FDA核准諾華公司的Pluvicto（镥Lu 177 vipivotide tetraxetan）用於治療晚期前列腺癌（前列腺特異性膜抗原陽性轉移性去勢抵抗性前列腺癌（PSMA陽性mCRPC））成年患者。 2023年4月，FDA授予Lantheus Holdings Inc和POINT Biopharma Global Inc 177Lu-PNT2002的快速通道資格，旨在治療轉移性去勢抵抗性前列腺癌（mCRPC）。 PNT2002是一種創新的PSMA靶向177Lu放射性藥物療法，它將PSMA靶向配體PSMA-I&T與BETA發射放射性同位素（無載體添加177Lu）相結合，用於轉移性去勢抵抗性前列腺癌（mCRPC）治療。競爭格局和主要公司：前列腺癌治療市場的知名企業包括安斯泰來製藥公司、強生服務公司、禮來公司、拜耳公司、賽諾菲、默克公司、阿斯特捷利康、諾華公司、艾伯維和百時美施貴寶。這些公司專注於推出新產品並進行地理擴張，以滿足不斷成長的全球需求並增強其特色產品組合。他們的國際影響力使他們能夠滿足廣泛的客戶群，從而促進市場成長。

目錄

第1章：簡介

第 2 章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：前列腺癌治療市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：前列腺癌治療市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：前列腺癌治療市場－全球市場分析

  • 前列腺癌治療 - 全球市場概覽
  • 前列腺癌治療－全球市場及2030年預測

第7章：前列腺癌治療市場 - 收入分析 - 按療法，2020-2030 年

  • 概述
  • 荷爾蒙療法
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他

第 8 章：前列腺癌治療市場 - 收入分析 - 按配銷通路，2020-2030 年

  • 概述
  • 醫院
  • 專科診所
  • 其他

第9章：前列腺癌治療市場-收入分析，2020-2030-地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第10章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 11 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 12 章：前列腺癌治療市場 - 主要公司簡介

  • Johnson and Johnson Services, Inc.
  • Bayer AG
  • AstraZeneca
  • Astellas Pharma Inc
  • Eli, Lilly, and Company
  • Sanofi
  • AbbVie Inc.
  • Merck KGaA
  • Novartis AG
  • Bristol Myers Squibb

第 13 章：附錄

簡介目錄
Product Code: TIPRE00003423

The prostate cancer therapeutics market is projected to increase from US$ 17.37 billion in 2024 to US$ 30.83 billion by 2031, with an expected CAGR of 8.5% from 2025 to 2031.

Market Insights and Analyst Perspective:The prostate cancer therapeutics market is growing due to heightened R&D efforts aimed at developing new drug compounds, a rising incidence of prostate cancer cases, and increased government support for prostate cancer diagnostics. Furthermore, the availability of advanced products from market players is propelling market expansion. In January 2023, BDR Pharmaceutical introduced a generic version of Apalutamide, marketed as APATIDE, in India, which is used to treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

Growth Drivers and Challenges:Prostate cancer ranks among the most prevalent health issues for men, particularly those aged 50 and older. It is more common in men who are obese or have a family history of the disease. Often, prostate cancer develops silently without noticeable symptoms, making early detection challenging. Most prostate cancers begin in the peripheral zone of the prostate gland, and symptoms typically emerge only when the cancer grows large enough to press on the urethra, or when bone pain from metastasis occurs. Men aged 50 and above experiencing lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer. Globally, prostate cancer is the fifth leading cause of cancer-related deaths among men and the second most frequently diagnosed cancer. Although there has been a decline in prostate cancer incidence since 2000, cases of late-stage prostate cancer have been on the rise since 2010. Incidence and mortality rates vary significantly, with developed countries generally reporting higher incidence but lower mortality rates. In the US, the risk of prostate cancer is nearly four times higher than the global average. According to Novartis AG, approximately 1.4 million new prostate cancer cases and around 375,000 deaths were reported worldwide in 2020. The increasing global incidence of prostate cancer and low detection rates are key factors driving the growth of the prostate cancer therapeutics market.

Strategic Insights

Report Segmentation and Scope:The prostate cancer therapeutics market is categorized by therapy type, end user, and geography. By therapy type, it includes hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. By end user, it is divided into hospitals, specialty clinics, and others. Geographically, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The prostate cancer therapeutics market is segmented by therapy type into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. In 2022, the hormone therapy segment held the largest market share after chemotherapy, and it is expected to achieve the highest CAGR from 2022 to 2030. Chemotherapy remains a crucial treatment for prostate cancer, as it involves drugs that target and destroy both new and existing cancer cells. Chemotherapy can alleviate symptoms of metastatic prostate cancer, reduce tumor size, and enhance quality of life. Docetaxel (Taxotere) is the standard treatment for chemotherapy in patients resistant to hormone therapy, while cabazitaxel (Jevtana) has also been approved by the FDA for treating castration-resistant prostate cancer, particularly in patients whose cancer has progressed during docetaxel treatment.

Regional Analysis:The prostate cancer therapeutics market is analyzed by region, including North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the leading contributor to the global growth of the prostate cancer therapeutics market, while Asia Pacific is anticipated to exhibit the highest CAGR from 2022 to 2030. The growth of the prostate cancer therapeutics market in the US is primarily driven by the rising incidence of prostate cancer, new product launches, and government initiatives. For instance, in June 2023, AstraZeneca and MSD's Lynparza (olaparib) was approved in the US for treating adult patients with suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Additionally, in November 2023, the FDA approved enzalutamide, manufactured by Astellas Pharma US, Inc., for treating non-metastatic castration-sensitive prostate cancer (nmCSPC) with a high risk of metastasis.

Prostate Cancer Therapeutics Market Report ScopeIndustry Developments and Future Opportunities:Key initiatives by major players in the prostate cancer therapeutics market include:

In March 2022, the US FDA approved Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients with advanced prostate cancer known as prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).

In April 2023, the FDA granted fast track designation to Lantheus Holdings Inc and POINT Biopharma Global Inc for 177Lu-PNT2002, aimed at treating metastatic castration-resistant prostate cancer (mCRPC). PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines a PSMA-targeted ligand, PSMA-I&T, with a beta-emitting radioisotope, no-carrier-added 177Lu for mCRPC treatment.Competitive Landscape and Key Companies:Prominent players in the prostate cancer therapeutics market include Astella Pharma Inc, Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie, and Bristol Myers Squibb. These companies focus on launching new products and expanding geographically to meet the growing global demand and enhance their specialty product portfolios. Their international presence enables them to cater to a broad customer base, thereby facilitating market growth.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Prostate Cancer Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Prostate Cancer Therapeutics Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Prostate Cancer Therapeutics Market - Global Market Analysis

  • 6.1 Prostate Cancer Therapeutics - Global Market Overview
  • 6.2 Prostate Cancer Therapeutics - Global Market and Forecast to 2030

7. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million) - By Therapy, 2020-2030

  • 7.1 Overview
  • 7.2 Hormonal Therapy
  • 7.3 Chemotherapy
  • 7.4 Targeted Therapy
  • 7.5 Immunotherapy
  • 7.6 Others

8. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Others

9. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Prostate Cancer Therapeutics Market Overview
    • 9.1.2 North America Prostate Cancer Therapeutics Market Revenue and Forecasts to 2030
    • 9.1.3 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Therapy
    • 9.1.4 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 9.1.5 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Prostate Cancer Therapeutics Market
        • 9.1.5.1.1 United States Prostate Cancer Therapeutics Market, by Therapy
        • 9.1.5.1.2 United States Prostate Cancer Therapeutics Market, by Distribution Channel
      • 9.1.5.2 Canada Prostate Cancer Therapeutics Market
        • 9.1.5.2.1 Canada Prostate Cancer Therapeutics Market, by Therapy
        • 9.1.5.2.2 Canada Prostate Cancer Therapeutics Market, by Distribution Channel
      • 9.1.5.3 Mexico Prostate Cancer Therapeutics Market
        • 9.1.5.3.1 Mexico Prostate Cancer Therapeutics Market, by Therapy
        • 9.1.5.3.2 Mexico Prostate Cancer Therapeutics Market, by Distribution Channel
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Prostate Cancer Therapeutics Market - Key Company Profiles

  • 12.1 Johnson and Johnson Services, Inc.
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Bayer AG
  • 12.3 AstraZeneca
  • 12.4 Astellas Pharma Inc
  • 12.5 Eli, Lilly, and Company
  • 12.6 Sanofi
  • 12.7 AbbVie Inc.
  • 12.8 Merck KGaA
  • 12.9 Novartis AG
  • 12.10 Bristol Myers Squibb

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud